Literature DB >> 17720884

Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells.

Joanne R Flavell1, Karl R N Baumforth, Victoria H J Wood, Gillian L Davies, Wenbin Wei, Gary M Reynolds, Susan Morgan, Andrew Boyce, Gemma L Kelly, Lawrence S Young, Paul G Murray.   

Abstract

The Epstein-Barr virus (EBV) contributes to the growth and survival of Hodgkin lymphoma (HL) cells. Here we report that down-regulation of the transforming growth factor-beta (TGF-beta) target gene, protein tyrosine phosphatase receptor kappa (PTPRK), followed EBV infection of HL cells and was also more frequently observed in the Hodgkin and Reed-Sternberg (HRS) cells of EBV-positive compared with EBV-negative primary HL. The viability and proliferation of EBV-positive HL cells was decreased by overexpression of PTPRK, but increased following the knockdown of PTPRK expression in EBV-negative HL cells, demonstrating that PTPRK is a functional tumor suppressor in HL. EBV suppressed the TGF-beta-mediated activation of PTPRK expression, suggesting disruption of TGF-beta signaling upstream of PTPRK. This was confirmed when we showed that the Epstein-Barr nuclear antigen-1 (EBNA1) decreased Smad2 protein levels and that this was responsible for PTPRK down-regulation. EBNA1 decreased the half-life of Smad2 but did not interact with Smad2. By down-regulating Smad2 protein expression, EBNA1 apparently disables TGF-beta signaling, which subsequently decreases transcription of the PTPRK tumor suppressor. We speculate that loss of the phosphatase function of PTPRK may activate as-yet-unidentified growth-promoting protein tyrosine kinases, which in turn contribute to the pathogenesis of EBV-positive HL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17720884     DOI: 10.1182/blood-2006-11-059881

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

Review 1.  Tumour suppressor function of protein tyrosine phosphatase receptor-T.

Authors:  Anthony Scott; Zhenghe Wang
Journal:  Biosci Rep       Date:  2011-10       Impact factor: 3.840

2.  Cancer-derived mutations in the fibronectin III repeats of PTPRT/PTPrho inhibit cell-cell aggregation.

Authors:  Peng Zhang; Scott Becka; Sonya E L Craig; David T Lodowski; Susann M Brady-Kalnay; Zhenghe Wang
Journal:  Cell Commun Adhes       Date:  2009-12

Review 3.  Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Authors:  Joseph G Taylor; John G Gribben
Journal:  Semin Cancer Biol       Date:  2015-07-29       Impact factor: 15.707

4.  Receptor type protein tyrosine phosphatases (RPTPs) - roles in signal transduction and human disease.

Authors:  Yiru Xu; Gary J Fisher
Journal:  J Cell Commun Signal       Date:  2012-08-01       Impact factor: 5.782

Review 5.  Tumor-derived extracellular fragments of receptor protein tyrosine phosphatases (RPTPs) as cancer molecular diagnostic tools.

Authors:  Sonya E L Craig; Susann M Brady-Kalnay
Journal:  Anticancer Agents Med Chem       Date:  2011-01       Impact factor: 2.505

Review 6.  The biology of Hodgkin's lymphoma.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

7.  DNA methylation of membrane-bound tyrosine phosphatase genes in acute lymphoblastic leukaemia.

Authors:  W S Stevenson; O G Best; A Przybylla; Q Chen; N Singh; M Koleth; S Pierce; T Kennedy; W Tong; S-Q Kuang; G Garcia-Manero
Journal:  Leukemia       Date:  2013-09-18       Impact factor: 11.528

8.  EBV-positive Hodgkin lymphoma is associated with suppression of p21cip1/waf1 and a worse prognosis.

Authors:  Ting-Yun Liu; Shang-Ju Wu; Mi-Hsin Huang; Fei-Yun Lo; Mong-Hsun Tsai; Ching-Hwa Tsai; Su-Ming Hsu; Chung-Wu Lin
Journal:  Mol Cancer       Date:  2010-02-09       Impact factor: 27.401

9.  Transcription profiling of Epstein-Barr virus nuclear antigen (EBNA)-1 expressing cells suggests targeting of chromatin remodeling complexes.

Authors:  Ramakrishna Sompallae; Simone Callegari; Siamak Akbari Kamranvar; Maria G Masucci
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

10.  The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells.

Authors:  Anthony M Ford; Chiara Palmi; Clara Bueno; Dengli Hong; Penny Cardus; Deborah Knight; Giovanni Cazzaniga; Tariq Enver; Mel Greaves
Journal:  J Clin Invest       Date:  2009-03-16       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.